Heat Biologics, Inc.

Leading the Immuno-Oncology Revolution

Heat’s ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient's own immune system to destroy the cancer cells.

Learn more about our science

About Us

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

Learn more about Heat Biologics

Recent News

Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial

Read More

Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference

Read More

Events

January 25, 2016 - January 27, 2016

Phacilitate Immunotherapy World Conference

Learn More

November 18, 2015 - November 20, 2015

Annual Therapeutic Area Partnerships Meeting

Learn More

ImPACT Therapy

A First-In-Class Fully Human Cytotoxic T Cell Specific Adjuvant

Heat Biologics’ proprietary ImPACT technology transforms allogenic living cells into miniature osmotic pumps that continually secrete heat shock protein gp96, the most potent mammalian adjuvant ever described, along with its chaperoned antigens.

View our product pipeline